Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS
Hagens Berman announced a securities class action investigation against Regeneron Pharmaceuticals concerning disclosures related to the failed Phase 3 trial of Fianlimab and Libtayo. The lawsuit alleges Regeneron made false statements regarding the trial protocol and failed to disclose that statistical assumptions were flawed and the primary endpoint was unlikely to be achieved.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.